Personalis (PSNL) Stock Price, News & Analysis

Company Overview

Personalis, Inc. is a genomics company focused on precision oncology and advanced molecular testing. The company develops and commercializes genomic products designed to help identify, monitor and characterize cancer, supporting more informed treatment decisions and the development of targeted therapies.

Its offerings include tissue- and blood-based tumor profiling, liquid biopsy testing and immune profiling. Personalis’ technologies are designed to detect and track tumor-derived signals, evaluate genomic alterations and provide insights into the interaction between cancer and the immune system. These capabilities support pharmaceutical and biotechnology companies in drug discovery, clinical trials and biomarker development, as well as healthcare organizations involved in cancer care.

Founded in 2011 and headquartered in Menlo Park, California, Personalis has worked with biopharmaceutical companies, academic medical centers and other research organizations. The company became publicly traded on the Nasdaq Stock Market in 2019. Its leadership includes Chief Executive Officer Chris Bauer, who oversees the company’s efforts to advance genomics-based tools for oncology research and patient management.

Key Stats

• Today's Range: $16.38 to $16.77
• 50-Day Range: $11.73 to $18.38
• 52-Week Range: $4.95 to $18.89
• Volume: 1.01 million shs
• Average Volume: 2.35 million shs
• Market Capitalization: $1.72 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.54
• Consensus Rating: Hold

Personalis Stock Analysis - MarketRank™

Personalis scored higher than 39% of companies evaluated by MarketBeat, and ranked 697th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.2 / 5
• Analyst Rating: Hold

Consensus Rating

Personalis has received a consensus rating of Hold. The company's average rating score is 2.30, and is based on no strong buy ratings, 4 buy ratings, 5 hold ratings, and 1 sell rating.

Downside Risk

Personalis has a consensus price target of $14.54, representing about 11.7% downside from its current price of $16.46.

Amount of Analyst Coverage

Personalis has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Personalis are expected to grow in the coming year, from ($1.07) to ($0.78) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Personalis is -15.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Personalis is -15.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Personalis has a P/B Ratio of 5.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

8.24% of the float of Personalis has been sold short.

Short Interest Ratio / Days to Cover

Personalis has a short interest ratio ("days to cover") of 3.55, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Personalis has recently decreased by 1.41%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Personalis does not currently pay a dividend.

Dividend Growth

Personalis does not have a long track record of dividend growth.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 0.56

News Sentiment

Personalis has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 16 news articles for Personalis this week, compared to 4 articles on an average week.

Search Interest

5 people have searched for PSNL on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.

MarketBeat Follows

4 people have added Personalis to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Personalis insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,835,152.00 in company stock.

Percentage Held by Insiders

4.20% of the stock of Personalis is held by insiders.

Percentage Held by Institutions

61.91% of the stock of Personalis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/04/2026
• Today: 9/26/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:PSNL
• CIK: 1527753
• Web: www.personalis.com
• Phone: (650) 752-1300
• Fax: N/A
• Employees: 260
• Year Founded: 2011

Price Target and Rating

• Average Price Target for Personalis: $14.54
• High Price Target: $17.00
• Low Price Target: $10.00
• Potential Upside/Downside: -11.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.30
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.09)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$81.27 million
• Net Margins: -153.84%
• Pretax Margin: -153.79%
• Return on Equity: -46.47%
• Return on Assets: -35.30%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.28
• Quick Ratio: 5.08

Sales & Book Value

• Annual Sales: $69.65 million
• Price / Sales: 24.75
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.94 per share
• Price / Book: 5.60

Miscellaneous

• Outstanding Shares: 104,720,000
• Free Float: 100,323,000
• Market Cap: $1.72 billion
• Optionable: Optionable
• Beta: 2.31